PMID- 30791765
OWN - NLM
STAT- MEDLINE
DCOM- 20190716
LR  - 20190716
IS  - 1747-4132 (Electronic)
IS  - 1747-4124 (Linking)
VI  - 13
IP  - 3
DP  - 2019 Mar
TI  - Efficacy and safety of selective internal radiotherapy versus sorafenib for 
      intermediate-locally advanced hepatocellular carcinoma: a systematic review and 
      meta-analysis.
PG  - 271-279
LID - 10.1080/17474124.2019.1570135 [doi]
AB  - BACKGROUND: Sorafenib (SOR) is recommended for locally advanced and metastatic 
      hepatocellular carcinoma (HCC), but the tolerability of SOR is unsatisfactory. 
      Selective internal radiotherapy (SIRT) has shown efficacy in intermediate-locally 
      advanced HCC patients. This meta-analysis aimed to compare the efficacy and 
      safety of SIRT and SOR in the treatment of intermediate-locally advanced HCC. 
      METHODS: We systematically searched the PubMed, Embase, Cochrane Library and Web 
      of Science databases for eligible studies. The endpoints evaluated included the 
      overall survival (OS), disease control rate (DCR), objective response rate (ORR) 
      and grade>/=3 adverse events (AEs). RESULTS: Six studies were included in this 
      analysis. The OS was similar between the two groups (HR 1.06, 95%CI 0.93-1.20; P 
      = 0.40). There was no difference in the DCR between the two groups (RR 1.13, 
      95%CI 0.87-1.46; P = 0.35). However, the ORR in the SIRT group was significantly 
      higher than that in the SOR group (RR 4.10, 95%CI 1.92-8.76; P = 0.0003). The 
      incidence rate of grade>/=3 AEs was higher in the SOR group. CONCLUSIONS: In 
      patients with intermediate-locally advanced HCC, SIRT and SOR result in similar 
      survival rates. The improved toxicity profile of SIRT may help when choosing 
      between the two treatments.
FAU - Zou, Jingwen
AU  - Zou J
AD  - a Oncology Center , Zhujiang Hospital of Southern Medical University , Guangzhou 
      , Guangdong Province , China.
FAU - Zhu, Weiliang
AU  - Zhu W
AD  - a Oncology Center , Zhujiang Hospital of Southern Medical University , Guangzhou 
      , Guangdong Province , China.
FAU - Meng, Hui
AU  - Meng H
AD  - a Oncology Center , Zhujiang Hospital of Southern Medical University , Guangzhou 
      , Guangdong Province , China.
FAU - Luo, Peng
AU  - Luo P
AUID- ORCID: 0000-0002-8215-2045
AD  - a Oncology Center , Zhujiang Hospital of Southern Medical University , Guangzhou 
      , Guangdong Province , China.
FAU - Zhang, Jian
AU  - Zhang J
AUID- ORCID: 0000-0001-7217-0111
AD  - a Oncology Center , Zhujiang Hospital of Southern Medical University , Guangzhou 
      , Guangdong Province , China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190125
PL  - England
TA  - Expert Rev Gastroenterol Hepatol
JT  - Expert review of gastroenterology & hepatology
JID - 101278199
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Hepatocellular/mortality/pathology/*therapy
MH  - Clinical Decision-Making
MH  - Humans
MH  - Liver Neoplasms/mortality/pathology/*therapy
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - *Radiotherapy Dosage
MH  - Risk Factors
MH  - Sorafenib/adverse effects/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Radioembolization
OT  - TARE
OT  - intra-arterial treatment
OT  - targeted therapy
OT  - vascular invasion
EDAT- 2019/02/23 06:00
MHDA- 2019/07/17 06:00
CRDT- 2019/02/23 06:00
PHST- 2019/02/23 06:00 [entrez]
PHST- 2019/02/23 06:00 [pubmed]
PHST- 2019/07/17 06:00 [medline]
AID - 10.1080/17474124.2019.1570135 [doi]
PST - ppublish
SO  - Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):271-279. doi: 
      10.1080/17474124.2019.1570135. Epub 2019 Jan 25.